(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.01%) $80.07
(1.60%) $2.67
(1.05%) $2 442.70
(4.27%) $32.60
(1.34%) $1 104.60
(-0.08%) $0.919
(-0.14%) $10.66
(-0.03%) $0.787
(0.08%) $91.04
Q4/2023
Generated By Getagraph.com: 2023-12-31
Regeneron Pharmaceuticals [REGN]
1.48% $ 982.29
Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
The financial data for REGN in Q4 2023 demonstrates impressive performance. The company achieved a total revenue of $3.43B, resulting in a remarkable gross profit of $3.22B and a robust gross profit ratio of 93.88%. The operating income stands at $972.9M, contributing to a significant net income of $1.16B. These figures indicate the company's strong financial position, evident in the total assets of $33.08B and total stockholders' equity of $30.51B.
Key insights from the financial report reveal REGN's exceptional ability to generate revenue and manage costs effectively, positioning the company for continued success in the market.
Total Revenue | $3.43B |
Gross Profit | $3.22B |
Net Income | $1.16B |
Total Assets | $33.08B |
Total Stockholders' Equity | $30.51B |
Revenues Q4 - 2023
Revenue | Gross Profit | Operating Expenses | Interest Expense | EBITDA | Net Income | EPS |
---|---|---|---|---|---|---|
$3.43B | $2.92B | $1.91B | $18.30M | $1.26B | $1.16B | $10.88 |
Balance Q4 - 2023
Net Income | Depreciation and Amortization | Stock Based Compensation | Change in Working Capital | Net Cash Provided by Operating Activities | Capital Expenditure | Free Cash Flow |
---|---|---|---|---|---|---|
$1.16B | $113.00M | $240.40M | $-61.40M | $1.09B | $-313.50M | $776.20M |